Ferrer has announced that its 2022 agreement with United Therapeutics for distribution rights to Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada, Israel, Japan, and China has been modified to add two more indications: idiopathic pulmonary ibrosis (IPF) and progressive pulmonary fibrosis (PPF). Two Phase 3 trials of Tyvaso in IPF are underway, and United Therapeutics announced the initiation of a Phase 3 trial of Tyvaso for PPF in October 2023.
According to Ferrer, the company has recently received marketing authorization for Tyvaso for the treatment of PH-ILD in Chile and the Dominican Republic. Obtaining marketing authorization in the United Kingdom is a priority, the company said.
Ferrer Chief Scientific and Business Development Officer Óscar Pérez commented, “The pulmonary vascular and interstitial lung diseases field is very important for us. Strengthening our partnership with United Therapeutics Corporation can advance our purpose of using business to fight for social justice through the delivery of new solutions for people, families and caregivers living with devastating diseases.”
Read the Ferrer press release.
